These enzymes are also involved in asthma and other autoimmune conditions which make those diseases possible targets for TRV 509 in the future said Jennifer Dovey Trivenis chief scientific officer. Its the size and way it can interact with a protease that makes antibodies the perfect modality to target these types of targets in a very selective and potent way Dovey said